Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

To join this study, people need to have bowel cancer that has been confirmed by a lab test and has spread. Doctors will need to know specific information about your cancer, like its 'RAS' status and confirmation that it's 'microsatellite stable' or 'MSI-low' – tests that your doctor will have done. You must have already tried standard cancer treatments for your advanced bowel cancer, and your cancer must have either grown or you couldn't continue those treatments.

You also need to have cancer that can be measured on scans, which helps doctors track how well the treatment is working. Your general health and fitness, measured by something called an 'ECOG performance status' (which means you're generally active and can look after yourself), should be good. You'll also need to have healthy organ function, like your liver and kidneys. For women who could become pregnant and their partners, it's important to agree to use effective birth control during and after the study.

However, you won't be able to join if you've already had certain specific treatments, including XL092, regorafenib, or particular types of immune medicines. Also, if you've recently had other small molecule kinase inhibitor drugs (including those used in other research studies) in the last two weeks, you wouldn't be able to take part.

If you decide to take part in this study, you would receive either the combination of XL092 and atezolizumab, or the drug regorafenib. You wouldn't get to choose which one; this is decided randomly, like flipping a coin. You would have regular visits to the clinic for medical check-ups, blood tests, and scans to see how your cancer is responding to the treatment. Doctors would also carefully monitor you for any side effects from the medication. The exact number of visits and the total length of the study would be discussed with you by the study team, but it will involve ongoing treatment and follow-up for as long as the treatment is benefiting you, and potentially beyond.